During the last session, Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares were 11.02 million, with the beta value of the company hitting 1.98. At the end of the trading day, the stock’s price was $1.36, reflecting an intraday loss of -7.48% or -$0.11. The 52-week high for the PACB share is $14.55, that puts it down -969.85 from that peak though still a striking 8.09% gain since the share price plummeted to a 52-week low of $1.25. The company’s market capitalization is $370.30M, and the average trade volume was 9.84 million shares over the past three months.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Pacific Biosciences of California Inc (PACB) registered a -7.48% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.48% in intraday trading to $1.36, hitting a weekly high. The stock’s 5-day price performance is -2.86%, and it has moved by -62.33% in 30 days. Based on these gigs, the overall price performance for the year is -87.44%.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Statistics show that Pacific Biosciences of California Inc has underperformed its competitors in share price, compared to the industry in which it operates. Pacific Biosciences of California Inc (PACB) shares have gone down -81.27% during the last six months, with a year-to-date growth rate less than the industry average at 9.01% against 14.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 25.00% this quarter and then jump 10.70% in the quarter after that. In the rating firms’ projections, revenue will increase 2.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $42.96 million as predicted by 11 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to $46.63 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $34.38 million .
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.76%. While earnings are projected to return 15.58% in 2024, the next five years will return -1.00% per annum.
PACB Dividends
Pacific Biosciences of California Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
